Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, ...

In the third quarter of 2024, GeneSight revenue per test improved both on a year-over-year and quarter-over-quarter basis, reflecting strong provider demand, commercial pull through and improving ...

NEW YORK – NeuroKaire on Tuesday said it has secured $10 million through a financing round, which it will use to continue developing a test for personalizing depression treatments, scale operations, ...

I was diagnosed with general anxiety disorder when I was very young—I think I may have been in elementary school. Those early ...

Almost half of all UK adults regularly take prescription medicines and the annual NHS budget for medicines is approximately £17.4 billion per year, with over 1.1 billion items prescribed ...

SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with ...

While Myriad continues to engage with UNH, the company reaffirms this estimate. The GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for more than 60 ...

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine class of drugs. TPMT∗8 is relatively common in individuals of African or ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication ...

predictive testing, and pharmacogenomic testing. Carrier Testing: This type of testing helps identify individuals who carry genes for specific genetic disorders and may pass them on to their children.